Bioactive Polycyclic Quinones from Marine Streptomyces sp. 182SMLY

Ying Liang, Xin Xie, Lu Chen, Shi‐Lun Yan, Xuewei Ye, Komal Anjum, Haocai Huang, Xiao‐Yuan Lian, Zhizhen ZhangMarine 2016 · DOI

TL;DR

Researchers have isolated two novel polycyclic quinone compounds, N-acetyl-N-demethylmayamycin and streptoanthraquinone A, from a marine bacterium. These compounds show significant promise as anti-cancer agents, effectively inhibiting the growth of various glioma cell lines and inducing apoptosis, while exhibiting a favorable selectivity over normal cells.

What Problem Does This Paper Address?

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer, and despite advances in treatment, patient outcomes remain poor. Current therapies, including surgery, radiation, and chemotherapy, have limited efficacy, and the development of new, effective anti-glioma drugs is a critical unmet need. Natural products, particularly those derived from marine organisms, have historically been a rich source of novel drug leads. This paper addresses the urgent need for new anti-glioma agents by exploring the chemical diversity of marine-derived microorganisms, specifically Streptomyces species, in the search for bioactive compounds.

Methods

The researchers employed a multi-faceted approach to identify and characterize the bioactive compounds:

  • Isolation and Purification: The marine bacterium Streptomyces sp. 182SMLY was cultured, and its extract was subjected to extensive column chromatography and High-Performance Liquid Chromatography (HPLC) to isolate the target compounds.
  • Structural Elucidation: The structures of the isolated compounds were determined using a suite of advanced spectroscopic techniques:
  • High-Resolution Electrospray Ionization Mass Spectrometry (HRESIMS): Used to determine the accurate molecular formulas of the compounds.
  • Nuclear Magnetic Resonance (NMR) Spectroscopy: Extensive 1D (¹H, ¹³C) and 2D (COSY, HSQC, HMBC, NOESY) NMR experiments were crucial for assigning atom connectivity and elucidating the detailed structures.
  • Electronic Circular Dichroism (ECD) Calculation: Theoretical ECD calculations were performed in conjunction with experimental ECD spectra to determine the absolute configurations of the chiral centers within the molecules.
  • Bioactivity Assays:
    • Cytotoxicity Assay (SRB): The isolated compounds were tested for their ability to inhibit the proliferation of four different human and rat glioma cell lines (U251, U87-MG, SHG-44, and C6) and normal human astrocytes (HA). Doxorubicin was used as a positive control.
  • Apoptosis Assay (Flow Cytometry): The ability of the compounds to induce apoptosis (programmed cell death) in glioma cells was assessed using Annexin V-FITC/PI double staining and flow cytometry.
  • Antimicrobial Assay (Micro Broth Dilution): The compounds were evaluated for their activity against methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. Norfloxacin was used as a positive control.

Datasets

Not discussed in the paper. The study relies on established cell lines and bacterial strains for bioactivity testing.

Key Insights and Ideas

  • Novelty in Marine Natural Products: The discovery of two new polycyclic quinones, N-acetyl-N-demethylmayamycin (1) and streptoanthraquinone A (2), highlights the untapped potential of marine microorganisms as sources of structurally unique and biologically active compounds.
  • Targeted Anti-Glioma Activity: Both compounds demonstrated significant inhibitory effects on glioma cell proliferation, with IC50 values in the low micromolar range. This is particularly encouraging given the challenges in developing effective treatments for gliomas.
  • Selective Toxicity: A crucial finding is the differential toxicity of these compounds. They showed significantly higher toxicity towards glioma cells compared to normal human astrocytes, suggesting a potential for reduced side effects in therapeutic applications. The calculated ratios of IC50 for astrocytes to glioma cells (6.4–53 for compound 1 and >14–31 for compound 2) underscore this selectivity.
  • Induction of Apoptosis: The compounds actively promote programmed cell death in glioma cells, which is a desirable mechanism for anti-cancer drugs as it leads to the elimination of cancer cells.
  • Unique Structural Features: Streptoanthraquinone A possesses a rare oxygen-contained hexatomic ring (ring F) at a unique position (C-6 and C-7), making its skeleton distinct from previously reported dihydrobenzo[a]naphthacenequinones. This structural novelty could be key to its biological activity.
  • Antibacterial Potential: N-acetyl-N-demethylmayamycin (1) also exhibited activity against MRSA, indicating a potential dual role as an anti-cancer and antibacterial agent.

Key Results

  • Compound 1 (N-acetyl-N-demethylmayamycin):
    • Inhibited glioma cell proliferation with IC50 values ranging from 0.5 to 3.9 µM.
  • Showed selectivity against normal human astrocytes with IC50 values of 25 µM, resulting in IC50HA/IC50gc ratios of 6.4–53.
  • Induced apoptosis in glioma U251 cells (38.76% increase in total apoptotic cells).
  • Inhibited MRSA growth with a Minimum Inhibitory Concentration (MIC) of 20.0 µM.
  • Compound 2 (Streptoanthraquinone A):
    • Inhibited glioma cell proliferation with IC50 values ranging from 3.3 to 7.3 µM.
  • Showed selectivity against normal human astrocytes with IC50 values >100 µM, resulting in IC50HA/IC50gc ratios of >14–31.
  • Induced apoptosis in glioma U251 cells (36.67% increase in total apoptotic cells).
  • Comparison to Doxorubicin: The tested compounds showed comparable or better activity and selectivity than the positive control doxorubicin in some cases.

Limitations and Future Work

  • Limited Scope of Antimicrobial Activity: While compound 1 showed activity against MRSA, neither compound was active against E. coli. Further exploration of antimicrobial spectrum might be warranted.
  • In Vitro Focus: The current study is primarily based on in vitro assays. Further in vivo studies are necessary to confirm the efficacy and safety of these compounds in animal models and eventually in human clinical trials.
  • Mechanism of Action: While apoptosis induction was observed, a deeper understanding of the precise molecular mechanisms by which these compounds exert their anti-glioma effects would be beneficial.
  • Structure-Activity Relationship (SAR): Further studies could involve synthesizing analogs of these compounds to explore structure-activity relationships and optimize their potency and selectivity.
  • Total Synthesis: The paper notes that the total synthesis of mayamycin (a related compound) is still underway. Developing efficient synthetic routes for these novel compounds would be crucial for large-scale production and further investigation.

Summary updated

Abstract

Chemical investigation of the cultures of marine Streptomyces sp. 182SMLY led to the discovery of two new polycyclic anthraquinones, which were elucidated as N-acetyl-N-demethylmayamycin (1) and streptoanthraquinone A (2) based on the extensive spectroscopic analysis including 2D NMR, HRESIMS, and an electronic circular dichroism (ECD) calculation. Both anthraquinones remarkably suppressed the proliferation of four different glioma cell lines with IC50 values in a range from 0.5 to 7.3 μM and induced apoptosis in the glioma cells. The ratios of IC50 for normal human astrocytes to IC50 for glioma cells were 6.4-53 for 1 and >14-31 for 2. N-acetyl-N-demethylmayamycin (1) also inhibited the growth of methicillin-resistant Staphylococcus aureus with MIC 20.0 μM.
BibTeX
@inproceedings{liang2016bioactive,
  author = {Ying Liang and Xin Xie and Lu Chen and Shi‐Lun Yan and Xuewei Ye and Komal Anjum and Haocai Huang and Xiao‐Yuan Lian and Zhizhen Zhang},
  title = {{Bioactive Polycyclic Quinones from Marine Streptomyces sp. 182SMLY}},
  booktitle = {Marine},
  year = {2016},
  doi = {10.3390/md14010010},
}
Figure